CN1604780A - 在前痴呆状态中使用罗苏伐他汀 - Google Patents
在前痴呆状态中使用罗苏伐他汀 Download PDFInfo
- Publication number
- CN1604780A CN1604780A CNA028253477A CN02825347A CN1604780A CN 1604780 A CN1604780 A CN 1604780A CN A028253477 A CNA028253477 A CN A028253477A CN 02825347 A CN02825347 A CN 02825347A CN 1604780 A CN1604780 A CN 1604780A
- Authority
- CN
- China
- Prior art keywords
- dementia
- rosuvastatin
- cognitive
- patient
- risk
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pyrane Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE01035096 | 2001-10-19 | ||
| SE0103509A SE0103509D0 (sv) | 2001-10-19 | 2001-10-19 | Rosuvastatin in pre demented states |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1604780A true CN1604780A (zh) | 2005-04-06 |
Family
ID=20285721
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNA028253477A Pending CN1604780A (zh) | 2001-10-19 | 2002-10-18 | 在前痴呆状态中使用罗苏伐他汀 |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US20060229321A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP1446123A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2005505605A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20040058201A (cg-RX-API-DMAC7.html) |
| CN (1) | CN1604780A (cg-RX-API-DMAC7.html) |
| AR (1) | AR036891A1 (cg-RX-API-DMAC7.html) |
| BR (1) | BR0213434A (cg-RX-API-DMAC7.html) |
| CA (1) | CA2463597A1 (cg-RX-API-DMAC7.html) |
| CO (1) | CO5580773A2 (cg-RX-API-DMAC7.html) |
| HU (1) | HUP0401798A3 (cg-RX-API-DMAC7.html) |
| IL (1) | IL161380A0 (cg-RX-API-DMAC7.html) |
| IS (1) | IS7218A (cg-RX-API-DMAC7.html) |
| MX (1) | MXPA04003631A (cg-RX-API-DMAC7.html) |
| NO (1) | NO20041840L (cg-RX-API-DMAC7.html) |
| PL (1) | PL369573A1 (cg-RX-API-DMAC7.html) |
| RU (1) | RU2004112422A (cg-RX-API-DMAC7.html) |
| SE (1) | SE0103509D0 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2003032995A1 (cg-RX-API-DMAC7.html) |
| ZA (1) | ZA200402844B (cg-RX-API-DMAC7.html) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2537271A1 (en) | 2003-08-28 | 2005-03-17 | Teva Pharmaceutical Industries, Ltd. | Process for preparation of rosuvastatin calcium |
| GB0322552D0 (en) | 2003-09-26 | 2003-10-29 | Astrazeneca Uk Ltd | Therapeutic treatment |
| US7777034B2 (en) | 2003-11-24 | 2010-08-17 | Teva Pharmaceutical Industries Ltd. | Crystalline ammonium salts of rosuvastatin |
| CN1894221B (zh) | 2003-12-02 | 2012-08-08 | 特瓦制药工业有限公司 | 用于表征罗苏伐他汀的参照标准品 |
| US7179916B2 (en) | 2004-07-13 | 2007-02-20 | Teva Pharmaceutical Industries Ltd. | Process for the preparation of rosuvastatin |
| CA2680693A1 (en) | 2005-02-22 | 2006-08-31 | Teva Pharmaceutical Industries Ltd. | Preparation of rosuvastatin |
| WO2007022488A2 (en) | 2005-08-16 | 2007-02-22 | Teva Pharmaceutical Industries Ltd. | Crystalline rosuvastatin intermediate |
| WO2012073256A1 (en) | 2010-11-29 | 2012-06-07 | Cadila Healthcare Limited | Salts of rosuvastatin |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2648897B2 (ja) * | 1991-07-01 | 1997-09-03 | 塩野義製薬株式会社 | ピリミジン誘導体 |
| US7189703B2 (en) * | 1998-01-09 | 2007-03-13 | Intracell, Llc | Treatment and diagnosis of alzheimer's disease |
| AR022462A1 (es) * | 1999-02-06 | 2002-09-04 | Astrazeneca Uk Ltd | Uso de un agente que disminuye el colesterol |
| US20030100493A1 (en) * | 2001-07-19 | 2003-05-29 | Sol Weiss | Sublingual use of inhibitors in the biosynthesis of cholesterol |
-
2001
- 2001-10-19 SE SE0103509A patent/SE0103509D0/xx unknown
-
2002
- 2002-10-17 AR ARP020103895A patent/AR036891A1/es not_active Application Discontinuation
- 2002-10-18 US US10/492,971 patent/US20060229321A1/en not_active Abandoned
- 2002-10-18 CA CA002463597A patent/CA2463597A1/en not_active Abandoned
- 2002-10-18 IL IL16138002A patent/IL161380A0/xx unknown
- 2002-10-18 PL PL02369573A patent/PL369573A1/xx not_active Application Discontinuation
- 2002-10-18 JP JP2003535798A patent/JP2005505605A/ja active Pending
- 2002-10-18 KR KR10-2004-7005585A patent/KR20040058201A/ko not_active Withdrawn
- 2002-10-18 BR BR0213434-9A patent/BR0213434A/pt not_active Application Discontinuation
- 2002-10-18 HU HU0401798A patent/HUP0401798A3/hu unknown
- 2002-10-18 CN CNA028253477A patent/CN1604780A/zh active Pending
- 2002-10-18 MX MXPA04003631A patent/MXPA04003631A/es not_active Application Discontinuation
- 2002-10-18 EP EP02783893A patent/EP1446123A1/en not_active Withdrawn
- 2002-10-18 WO PCT/SE2002/001911 patent/WO2003032995A1/en not_active Ceased
- 2002-10-18 RU RU2004112422/14A patent/RU2004112422A/ru not_active Application Discontinuation
-
2004
- 2004-04-13 IS IS7218A patent/IS7218A/is unknown
- 2004-04-15 ZA ZA200402844A patent/ZA200402844B/en unknown
- 2004-04-19 CO CO04035705A patent/CO5580773A2/es not_active Application Discontinuation
- 2004-05-05 NO NO20041840A patent/NO20041840L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| WO2003032995A1 (en) | 2003-04-24 |
| PL369573A1 (en) | 2005-05-02 |
| CO5580773A2 (es) | 2005-11-30 |
| KR20040058201A (ko) | 2004-07-03 |
| BR0213434A (pt) | 2004-11-09 |
| ZA200402844B (en) | 2005-01-24 |
| HUP0401798A3 (en) | 2005-06-28 |
| RU2004112422A (ru) | 2005-04-10 |
| US20060229321A1 (en) | 2006-10-12 |
| WO2003032995A8 (en) | 2004-06-03 |
| NO20041840L (no) | 2004-05-05 |
| AR036891A1 (es) | 2004-10-13 |
| EP1446123A1 (en) | 2004-08-18 |
| HUP0401798A2 (hu) | 2005-01-28 |
| MXPA04003631A (es) | 2004-07-30 |
| SE0103509D0 (sv) | 2001-10-19 |
| CA2463597A1 (en) | 2003-04-24 |
| IS7218A (is) | 2004-04-13 |
| JP2005505605A (ja) | 2005-02-24 |
| IL161380A0 (en) | 2004-09-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Haustein et al. | Methotrexate in psoriasis: 26 years’ experience with low‐dose long‐term treatment | |
| JP2001517617A (ja) | 神経変性疾患の治療を目的としてａｐｏｅレベルを増加させる方法 | |
| Ohta et al. | A prospective clinical study of theophylline safety in 3810 elderly with asthma or COPD | |
| UA75614C2 (uk) | Спосіб лікування гетерозиготної родинної гіперхолестеринемії розувастатином (zd-4522) | |
| US10537566B2 (en) | Combinations comprising siponimod and laquinimod for the treatment of multiple sclerosis | |
| JP2020200352A (ja) | 特定の患者集団において神経変性障害を処置する方法 | |
| US20220133652A1 (en) | A formulation for improving seizure control | |
| JP2013521303A5 (cg-RX-API-DMAC7.html) | ||
| AU2014212740B2 (en) | PPARy agonists for treatment of multiple sclerosis | |
| Al-Ashwal et al. | Identification and treatment of patients with homozygous familial hypercholesterolaemia: information and recommendations from a middle east advisory panel | |
| JP2024543053A (ja) | 神経変性疾患の治療のための胆汁酸及びフェニルブチレート化合物の組合せ | |
| CN1604780A (zh) | 在前痴呆状态中使用罗苏伐他汀 | |
| TW201902471A (zh) | 賈卡賓尼（ｇｅｍｃａｂｅｎｅ）、其醫藥上可接受之鹽、彼等之組成物及使用彼等之方法 | |
| US20190298740A1 (en) | Methods and compositions for treating hallucinations and conditions related to the same | |
| US20230089715A1 (en) | Masitinib for the treatment of a multiple sclerosis patient subpopulation | |
| TW202410887A (zh) | 用於治療肌肉萎縮性脊髓側索硬化症之方法及組成物 | |
| TWI242431B (en) | Pharmaceutical compositions for treating pulmonary diseases | |
| KR20040029447A (ko) | Ｈｉｖ 요법에서의 아타자나비르의 용도 | |
| WO2022006392A1 (en) | Novel pharmaceutical compositions | |
| JP7668386B2 (ja) | １－（３－シアノ－１－イソプロピル－インドール－５－イル）ピラゾール－４－カルボン酸を含む薬学的組成物 | |
| WO2019004465A1 (ja) | ペマフィブラートを含有する医薬 | |
| MXPA06006831A (es) | Uso de estatinas para el tratamiento del sindrome metabolico. | |
| AU2002347698A1 (en) | Rosuvastatin in pre demented states | |
| US20230390276A1 (en) | Treatment of autoimmune diseases with a dihydroorotate hehydrogenase (dhodh) inhibitor | |
| JPWO2014034871A1 (ja) | 脂質異常症の予防又は治療薬 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |